Gut Liver.
2017 Jan;11(1):129-135. 10.5009/gnl15597.
Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study
- Affiliations
-
- 1Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea.
- 2Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. gudwns21@korea.ac.kr
- 3Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
- 4Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 5Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- 6Department of Internal Medicine, Seoul National University College of Medicine, Seongnam, Korea.
- 7Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
- 8Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
- 9Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
- 10Bundang Jesaeng Hospital, Seongnam, Korea.
- 11Department of Public Health, Wonkwang University Graduate School, Iksan, Korea.
- 12Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. gudwns21@korea.ac.kr
- KMID: 2412164
- DOI: http://doi.org/10.5009/gnl15597
Abstract
- BACKGROUND/AIMS
Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). This study evaluated the efficacy of different rescue therapies for CLV-resistant CHB.
METHODS
Patients with CLV-resistant CHB were enrolled in the cohort, and all patients developed virologic breakthrough during CLV therapy and had confirmed-genotypic resistance to CLV (rtM204I mutation) before enrollment.
RESULTS
Of the 107 patients, 12 received adefovir (ADV), 21 received a CLV plus ADV combination (CLV+ADV), 34 received a lamivudine plus ADV combination (LAM+ADV), and 40 received entecavir (ETV) therapy for 48 weeks. The CLV+ADV group had the lowest hepatitis B virus (HBV) DNA level (p<0.0001) and showed the greatest reduction of HBV DNA levels from baseline compared to all other groups (p=0.004) at week 48. HBV DNA was undetectable (<70 IU/mL) in 0%, 57.1%, 21.2%, and 27.5% (p=0.003) of the patients in each group, respectively, at week 48. At the end of the study, the mean alanine transaminase (ALT) level, rate of ALT normalization, and rate of hepatitis B envelope antigen loss or seroconversion did not differ between groups.
CONCLUSIONS
CLV+ADV combination therapy in patients with CLV-resistant CHB more effectively suppresses HBV replication than ETV, ADV, or LAM+ADV therapy.
Keyword
MeSH Terms
-
Adenine/*analogs & derivatives/therapeutic use
Adult
Aged
Antiviral Agents/*therapeutic use
Arabinofuranosyluracil/*analogs & derivatives/therapeutic use
Cohort Studies
DNA, Viral/blood
Disease Management
Drug Resistance, Viral/genetics
Drug Therapy, Combination
Female
Genotype
Guanine/*analogs & derivatives/therapeutic use
Hepatitis B virus/genetics
Hepatitis B, Chronic/blood/*drug therapy/virology
Humans
Lamivudine/*therapeutic use
Male
Middle Aged
Organophosphonates/*therapeutic use
Viral Load
Antiviral Agents
DNA, Viral
Organophosphonates
Lamivudine
Arabinofuranosyluracil
Guanine
Adenine
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy of New Anti-viral Agent in the Treatment of Chronic Hepatitis B
- Development of Clevudine Resistance after Switching from Lamivudine in a Patient with Chronic Hepatitis B
- Clevudine therapy in patients with chronic hepatitis B
- Clevudine induced diabetes mellitus in a patient with chronic hepatitis B
- Clinical and Virological Responses to Clevudine Therapy of Hepatocelluar Carcinoma Patients with Chronic Hepatitis B
